Skip to main content

Sickle Cell Disease and cannabis in Indiana

The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

Not on the qualifying list
✗ No
LEGAL
CBD products with ≤0.3%…
POSSESSION
$0/yr
STATE FEE
14–60 d
TIMELINE
Not on the qualifying list. The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

Indiana statute and program

The Indiana CBD Authorization (Industrial Hemp / Low-THC) is the operating authority for Indiana patient certification. The authoritative legal text is: Indiana Code 35-48-4-11: Possession of Marijuana.

What the evidence says about cannabis and Sickle Cell Disease

Sickle cell disease (SCD) is a group of inherited red blood cell disorders caused by mutations in the hemoglobin gene. Red cells assume a rigid sickle shape under low-oxygen conditions, leading to chronic hemolytic anemia, episodic vaso-occlusive pain crises, stroke risk, acute chest syndrome, and progressive end-organ damage. SCD disproportionately affects people of African, Mediterranean, and South Asian descent.

For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Sickle Cell Disease page.

How to qualify in Indiana

The Indiana CBD Authorization (Industrial Hemp / Low-THC) requires the following registration steps for a Sickle Cell Disease patient (or any qualifying diagnosis):

  1. Confirm a qualifying intractable epilepsy diagnosis. Indiana operates a narrow low-THC CBD authorization under IC 35-48-3-7.2 (the "Industrial Hemp / Low-THC CBD Act" enacted 2017). The authorization covers only treatment-resistant epilepsy. A patient or the patient’s caregiver registers with the Indiana State Department of Health after a physician confirms the diagnosis of intractable epilepsy.
  2. Register with the Indiana State Department of Health. The Indiana State Department of Health (ISDH) maintains a Therapeutic Hemp Extract registry. Patients submit a registration form and a copy of the physician’s diagnostic statement. There is no online portal; registration is handled by mail to ISDH.
  3. No state registration fee. Indiana does not charge a state registration fee under IC 35-48-3-7.2. The patient bears only the costs of the physician evaluation and the cost of CBD product obtained through legal channels.
  4. Possess low-THC CBD (≤0.3% THC) obtained through legal channels. Registered patients may possess CBD products containing not more than 0.3% THC by weight (the federal hemp threshold) for treatment of intractable epilepsy. Indiana does not authorize an in-state medical cannabis dispensary network, in-state cultivation, or higher-THC products. Indiana does not honor out-of-state medical cards. Adult-use cannabis remains illegal in Indiana.
State registration fee
$0
Physician visit (typical)
$150–$350
Certification to card
14–60 days
Out-of-state patients
Not eligible
Minors
Eligible with caregiver

For full Indiana registration steps, fees, and reciprocity rules, see the Indiana cannabis-laws page.

ICD-10 code

A certifying physician documenting Sickle Cell Disease for the Indiana medical cannabis program will typically record ICD-10 D57.1 or SNOMED-CT 417357006 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.

Frequently asked questions

Does Indiana list Sickle Cell Disease as a qualifying condition for medical cannabis?

No. Indiana's qualifying-condition list does not currently include Sickle Cell Disease, and the state's program does not give physicians open-ended discretion to add conditions outside the list. Patients with Sickle Cell Disease in Indiana have limited in-state pathways under the medical program as written. Options to verify and pursue include: petitioning the state regulator to add the condition (where the statute permits public petitions); consulting a physician about whether a co-occurring listed condition could support certification; or reviewing whether the state's program is undergoing legislative expansion. Indiana program rules change, so verify the current list with the regulator before drawing a final conclusion.

How do I get a Indiana medical marijuana card for Sickle Cell Disease?

Because Indiana does not currently list Sickle Cell Disease as a qualifying condition, a card for Sickle Cell Disease alone may not be obtainable in-state under the program rules as written. Step one is finding a physician licensed in Indiana who is registered with Indiana CBD Authorization (Industrial Hemp / Low-THC) and willing to evaluate Sickle Cell Disease cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. Indiana does not honor out-of-state cards, so the certification process has to originate inside the state. Verify the patient minimum age with the state program before applying. Confirm the current process with the state regulator before applying, because the rules change.

What does the evidence say about cannabis for Sickle Cell Disease?

For Sickle Cell Disease, evidence is described as limited (a small number of supportive studies, often underpowered or focused on narrow symptom domains). The mmjnow condition page for Sickle Cell Disease lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Sickle Cell Disease should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Sickle Cell Disease and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Sickle Cell Disease; the evidence position above describes whether trial data supports its use, not whether it should replace standard care.

Sources

  1. Indiana Code 35-48-4-11: Possession of Marijuanaaccessed May 15, 2026
  2. NORML: Indiana Lawsaccessed May 15, 2026
  3. Wikipedia: Cannabis in Indianaaccessed May 15, 2026
  4. Indiana Code 35-48-4-11: Possession of marijuana (full text)accessed May 17, 2026
  5. Indiana State Department of Agriculture: Industrial Hemp Programaccessed May 17, 2026
  6. Indiana General Assembly bill trackeraccessed May 17, 2026
  7. Marion County (Indianapolis) Prosecutor — small-amount possession discretion policy (2019)accessed May 17, 2026
  8. NIH National Heart, Lung, and Blood Institute: Sickle Cell Diseaseaccessed May 15, 2026
  9. NIH NCCIH: Cannabis (Marijuana) and Cannabinoidsaccessed May 15, 2026